NASDAQ · XBIT
Healthcare · Biotechnology
$2.20
Up+$0.09 (+4.09%)
Updated Oct 9, 2026, 11:18 PM
SID Score
4.7/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · XBIT
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 8, 2026
XBIT closed at $2.20 after 21 trading sessions, up 1.38% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 8, 2026 | $2.19 | $2.22 | $2.15 | $2.20 | 13.02K |
| Oct 7, 2026 | $2.16 | $2.23 | $2.16 | $2.19 | 100.38K |
| Oct 6, 2026 | $2.18 | $2.1897 | $2.16 | $2.16 | 11.71K |
| Oct 5, 2026 | $2.20 | $2.20 | $2.18 | $2.18 | 32.74K |
| Oct 2, 2026 | $2.20 | $2.20 | $2.19 | $2.19 | 25.24K |
| Oct 1, 2026 | $2.19 | $2.20 | $2.19 | $2.20 | 13.56K |
| Sep 30, 2026 | $2.18 | $2.21 | $2.18 | $2.19 | 62.85K |
| Sep 29, 2026 | $2.13 | $2.18 | $2.13 | $2.18 | 9.55K |
| Sep 28, 2026 | $2.16 | $2.19 | $2.15 | $2.15 | 41.69K |
| Sep 25, 2026 | $2.156 | $2.17 | $2.15 | $2.17 | 10.83K |
| Sep 24, 2026 | $2.17 | $2.19 | $2.16 | $2.16 | 24K |
| Sep 23, 2026 | $2.19 | $2.20 | $2.17 | $2.18 | 40.04K |
| Sep 22, 2026 | $2.21 | $2.21 | $2.18 | $2.18 | 9.1K |
| Sep 21, 2026 | $2.19 | $2.20 | $2.17 | $2.18 | 31.84K |
| Sep 18, 2026 | $2.20 | $2.22 | $2.16 | $2.19 | 66.09K |
| Sep 17, 2026 | $2.17 | $2.18 | $2.14 | $2.18 | 32.12K |
| Sep 16, 2026 | $2.19 | $2.22 | $2.15 | $2.15 | 49.07K |
| Sep 15, 2026 | $2.17 | $2.20 | $2.16 | $2.195 | 18.23K |
| Sep 14, 2026 | $2.20 | $2.2001 | $2.17 | $2.17 | 21.88K |
| Sep 11, 2026 | $2.19 | $2.21 | $2.18 | $2.19 | 31.33K |
| Sep 10, 2026 | $2.17 | $2.18 | $2.15 | $2.17 | 20.27K |
The latest Smart Investors Daily articles mentioning XBIT.
Company
Market Activity
Research & News
XBIT research
Company profile and research snapshot.
XBiotech Inc is a United States-based clinical-stage biopharmaceutical company. The company is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing Anti-inflammatory therapeutic antibodies as a treatment for cancer. Geographically, all of its operations are in the United States.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Apr 7, 2020 | Piper Sandler | Overweight | — |
| Dec 11, 2019 | PiperJaffray | Overweight | — |
| Jun 14, 2019 | Piper Jaffray | Overweight | — |
No generated briefing is available yet.
defenseworld.net · Dec 6, 2025
XBiotech Inc. (NASDAQ: XBIT - Get Free Report) passed above its 50 day moving average during trading on Friday. The stock has a 50 day moving average of $2.47 and traded as high as $2.68. XBiotech shares last traded at $2.48, with a volume of 87,170 shares changing hands. Analyst Upgrades and Downgrades Separately, Weiss
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning XBIT.
No results
No recent SID articles mention XBIT.
